PHILADELPHIA, Dec. 20, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that the Company has entered into an agreement with GP Pharm Latinoamerica ("GP Pharm"), an affiliate company of Spanish GP Pharm SA ( www.gp-pharm.com ) for the marketing of Alferon N Injection®, the Company's natural interferon injection product which has been FDA approved for a category of sexually transmitted diseases in Argentina with an option for other Latin American countries upon receipt of those respective countries' regulatory approval for any use of the product. Under this Agreement, the Company will manufacture and supply Alferon N Injection® to GP Pharm in Argentina under an exclusive Sales, Marketing, Distribution and Supply Agreement. Under this Agreement, GP Pharm will be responsible for gaining regulatory approval for each indication and commercializing Alferon N Injection® in Argentina. The Company has granted GP Pharm the right to expand its territory to include other Latin American countries based upon GP Pharm achieving regulatory approval and certain first sale performance milestones. Thomas Kenwood Equels, Executive Vice Chairman of Hemispherx and the leader of its world-wide marketing efforts, stated, "I am very pleased that we have broadened our relationship with GP Pharm to include Alferon N Injection®." Mr. Braver of GP Pharm said, "We are also excited to have the opportunity to market the FDA approved product, Alferon N Injection®, a natural interferon with a proven track record of safety and historically demonstrated exceptional anti-viral capabilities, in Argentina and potentially throughout Latin America." In June of 2010, the Company and GP Pharm entered into a similar Sales, Marketing, Distribution and Supply Agreement for regulatory approval and sale of Ampligen®, an experimental therapeutic, to treat Chronic Fatigue Syndrome ("CFS") for Argentina including the right to expand rights to sell this experimental therapeutic into other Latin American countries based upon GP Pharm's achieving regulatory approval and certain first sale performance milestones.